Enjoy complimentary customisation on priority with our Enterprise License!
The cancer immunotherapy market size is estimated to grow by USD 45.5 billion at a CAGR of 8.1% between 2023 and 2028. The high prevalence of cancer worldwide is increasing the demand for effective treatment options, driving the growth of the market. Growing awareness among consumers regarding the benefits of cancer immunotherapy, which offers targeted and personalized treatment options with potentially fewer side effects, is also driving market growth. Additionally, the strong R&D pipeline of monoclonal antibodies, which are a key component of many cancer biologics and immunotherapy treatments, is fueling innovation in the field and expanding treatment options for patients. Overall, these factors are creating a favorable market environment for cancer immunotherapy and driving advancements in cancer treatment.
The research and development pipeline of monoclonal antibodies is dominated by cancer immunotherapy system indications. Among these, in view of increasing cancer prevalence and the high uptake of monoclonal antibodies as treatment options, oncology drugs appear to be a major therapeutic area for monoclonal antibodies. Both large and small players are investing in the development of monoclonal antibodies, but Novartis has the largest pipeline for monoclonal antibodies. However, a very small fraction of monoclonal antibodies in R&D programs have reached the clinical and marketing phases for anti-infection and neuropharmacological monoclonal antibodies. The adoption of novel therapeutics in cancer immunotherapy is being aided by R&D activities for new technology.
To learn more about this report, Request Free Sample
The market share growth by the monoclonal antibodies segment will be significant during the forecast period. There has been a significant increase in the incidence of cancers globally. Monoclonal antibodies, including cancer monoclonal antibodies, are used for the diagnosis and treatment of many diseases, including some types of cancer. They may be used alone, or they may be carried directly to cancer cells by drugs, toxins, or radioactive substances.
Get a glance at the market contribution of various segments View a PDF Sample
The monoclonal antibodies segment was valued at USD 36.30 billion in 2018. In recent years, cancer treatment has been revolutionized by introducing several agents, such as monoclonal antibodies. As this is a cost-effective treatment, several distributors are developing it. Therefore, such factors will drive the growth of the monoclonal antibodies segment in the immunotherapy drugs segment during the forecast period.
Lung cancer
Lung cancer is a type of cancer that generally begins in the lungs and might spread to lymph nodes or other organs in the body. Factors like increases in smoking, radiation therapy, and others increase the risk factors and the chances of occurrence of lung cancer. One of the most prevalent types of cancer, lung cancer is the main reason for cancer deaths worldwide. Cancer immunotherapy such as lung cancer therapeutics helps in helps in controlling symptoms of advanced or metastatic lung cancer, and also kills cancer cells, and stops lung cancer cells from growing and spreading. The demand for cancer immunotherapy is rising due to rising cigarette usage and lung cancer prevalence worldwide. Therefore, the lung cancer segment will grow in the market during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America holds the largest share of the market owing to the vast investments made in the oncology sector in the US. The US dominates the regional market and acts as the primary revenue generator, followed by Canada. Significant factors supporting the US dominance in this part of the world as well as worldwide are, for example, significant investments in the pharmaceuticals sector, with an emphasis on oncology.
Moreover, Cancer is one of the most common chronic diseases in the US. Thus, with the growing incidences of cancer, companies will invest in extensive research to develop effective drugs to treat several cancers. As cancer drugs are associated with several side effects, the demand is expected to increase in the region during the forecast period.
Buy Now Full Report and Discover More
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Amgen Inc. - The company offers cancer immunotherapy solutions such as Oncolytic Immunotherapy, Amgen Oncology
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market is fueled by increasing awareness programs and government supervision, which are driving stringent regulations to ensure patient safety. Clinical trials play a crucial role in developing these therapies, despite their high product developmental cost. The market offers significant investment pockets for pharmaceutical companies, hospitals, and cancer research centers. Biologic therapies, including cytokines & immunomodulators and novel drugs like Quizartinib (Vanflyta) targeting FLT3, are at the forefront of this innovative approach, with many treatments showing promising results and gaining approval from regulatory bodies like the FDA. The market is experiencing significant growth as the healthcare industry shifts focus towards more personalized and effective treatments. Traditional therapy methods, such as chemotherapy and radiation, are being complemented by immunotherapies that harness the power of the body's own immune system to target and destroy cancer cells. One of the most promising developments in this field is the use of target therapies, such as Laherparepvec Talimogene and Repotrectinib, for the treatment of various types of cancer. For instance, Laherparepvec Talimogene, a type of immunotherapy known as oncolytic virus therapy, is being used to treat advanced, unresectable melanoma and has shown promising results in clinical trials. Meanwhile, Repotrectinib, a selective and potent TRK inhibitor, is being used for the treatment of solid tumors that have a NTRK gene fusion. These targeted therapies offer greater specificity and fewer side effects compared to traditional therapies.
As the use of immunotherapies continues to expand, the distribution channels for these treatments are also evolving. Hospital pharmacies and online pharmacies are both playing crucial roles in making these life-saving treatments more accessible to patients. With advancements in technology and logistics, online pharmacies are able to offer convenient and efficient options for patients to access these specialized therapies from the comfort of their own homes. In conclusion, the Cancer Immunotherapy Market is poised for continued growth as targeted therapies like Laherparepvec Talimogene and Repotrectinib offer new hope for patients with nonsmall cell lung cancer and other types of cancer. The role of hospital pharmacies and online pharmacies in making these treatments more accessible is also a significant development in the healthcare industry.
The high prevalence of cancer is driving growth in the market. Poor unhealthy habits, inactivity, and excessive use of tobacco and alcohol can lead to lung, stomach, kidney, head, neck, and larynx cancer. Exposure to ionizing radiations, chemical mutagens, infectious micro-organisms, and environmental pollutants can also contribute to the development of cancer.Additionally, with the aging population and a higher incidence of cancer, the costs associated with diagnosis and treatment are expected to increase. The adoption of new, more expensive treatments as the standard of care will also contribute to this cost escalation.
Furthermore, this underscores the importance of awareness programs, stringent regulations, and government supervision in managing these costs. Clinical trials and product developmental costs for treatments such as cytokines & immunomodulators are also significant factors. Hospitals and cancer research centers play crucial roles in addressing these challenges. To provide better treatment options, medical facilities require sensitive and reliable diagnostics for accurate and early cancer detection. Molecular and companion diagnostics are popular methods for detecting various cancer types.
The adoption of various strategies for market growth is a key trend in a significant market. To increase market share, suppliers are implementing various strategies. They form licensing agreements with other companies to commercialize their products worldwide, particularly in emerging countries.
Moreover, the companies have undertaken to collaborate or acquire to increase the global market share of cancer immunotherapies by using the technologies. companies also engage in capital investment and avail government support to develop and launch advanced or upgraded devices.
The presence of stringent regulatory policies is a major challenge in the market. The challenge to the growth of the cancer immunotherapies market is that there are strict regulations introduced by regulatory bodies all over the world. The US FDA has imposed stringent restrictions on the marketing approval and manufacturing of biosimilars.
However, the most important aspect is to provide a combination of biological, physicochemical, and clinical data, which are not required for novel drugs to demonstrate similarity with reference originators. Other details that companies must submit include dosage, route of administration, contraindications, warnings, and precautions, which, in turn, incur a high financial burden on the R&D of cancer immunotherapy.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments
The market is experiencing significant growth, driven by advancements in techniques that leverage the immune system to target cancer-specific targets. This approach is revolutionizing healthcare expenditure and medical insurance, offering promising outcomes for patients. Technological advancements have led to novel therapies for various cancers like melanoma, prostate cancer, and head & neck cancer, enhancing treatment options. Biologic therapy and the use of live viruses in treatment, such as AML and FMS, are at the forefront of R&D activities. Companies like Immatics and Moderna are pioneering strategic business planning for the development of therapies like PRAME203 TCRT and MARTE mRNA cancer vaccine. With a focus on geriatric populations and those with chronic orthopedic conditions, the market is poised for further growth, supported by advanced medical facilities and the utilization of cancer immunotherapy.
The market is influenced by rising new cases of cancer and deaths due to cancer, driving the need for effective treatments. Clinics play a crucial role in administering these therapies, enhancing immunity against diseases like AML and FMS. Organizations like the International Agency for Research on Cancer (IARC) contribute to research and development in this field. The Cancer Immunotherapy Market is witnessing significant growth due to the increasing prevalence of various types of cancer, such as lungs cancer, multiple myeloma, and acute myeloid leukemia, and the need for more effective and less toxic treatment options. Traditional chemotherapies have limitations, including damage to healthy cells. However, the advent of immunotherapies, such as monoclonal antibodies (mAbs) like Keytruda and Durvalumab, and Fms like tyrosine kinase inhibitors, is revolutionizing cancer treatment. Immunotherapies work by stimulating the immune response against cancer cells. Bioinformatics tools are used to identify potential targets for immunotherapies, such as specific proteins on cancer cells. For instance, mAbs like Keytruda and Durvalumab target specific proteins on cancer cells, while cart cell therapy, such as Blinatumomab, uses the patient's immune system to target cancer cells.
Oncolytic viral therapies and manmade proteins, such as Fms like tyrosine kinase, are also being explored in cancer immunotherapy. These treatments have shown promise in treating various types of cancer, including lungs cancer and multiple myeloma. The Cancer Immunotherapy Market is expected to grow significantly in the coming years, with the increasing availability of these treatments through hospital pharmacies and online pharmacies. Other emerging treatments, such as CAR T cell therapy and Sipuleucel-T, are also expected to contribute to the market's growth. Overall, cancer immunotherapy is a promising field that holds the key to more effective and less toxic cancer treatments.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Base year |
2023 |
|
Historic period |
2018 - 2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 8.1% |
|
Market growth 2024-2028 |
USD 45.5 billion |
|
Market structure |
USD Fragmented |
|
YoY growth 2023-2024(%) |
7.32 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 43% |
|
Key countries |
US, Germany, China, France, and Canada |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Amgen Inc., Amneal Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Dendreon Pharmaceuticals LLC, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Gilead Sciences Inc., GlaxoSmithKline Plc, Immunocore Holdings Plc, Inovio Pharmaceuticals Inc., Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi SA, Seagen Inc., and Takeda Pharmaceutical Co. Ltd. |
|
Market dynamics |
Parent market analysis, Market forecasting, market forecast, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, Market growth and Forecasting, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
